Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Daiichi Submit Prasugrel; Showdown With Plavix Timed For Second Half

Executive Summary

Lilly and Daiichi Sankyo plan to launch the antiplatelet drug prasugrel immediately after it is approved, supported by an extensive sales force including representatives from both companies

You may also be interested in...



AstraZeneca In The “Transparency” Era: An Interview With CEO David Brennan

If you visit AstraZeneca's offices in Washington, D.C., your name has to be on a list. After you get your badge, you show it at the elevator bank to a guard, who, in a throwback to operators of yore, steps inside with you to unlock the keypad and send you on your way

AstraZeneca In The “Transparency” Era: An Interview With CEO David Brennan

If you visit AstraZeneca's offices in Washington, D.C., your name has to be on a list. After you get your badge, you show it at the elevator bank to a guard, who, in a throwback to operators of yore, steps inside with you to unlock the keypad and send you on your way

The Year Ahead: Controversial NDAs Could Entangle FDA In ‘08; Where Are The Oncologics?

Looking ahead at FDA's review calendar for 2008, the agency will be wrestling with several enigmatic decisions as it considers applications for fibromyalgia and chronic fatigue syndrome, controversial diseases with nebulous definitions and diagnoses

Related Content

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel